Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s EBIT?
- Tarsus Pharmaceuticals, Inc. (TARS) reported EBIT of -$19.91M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s EBIT increased by 10.3% year-over-year, from -$22.18M to -$19.91M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s EBIT has grown at a 55.4% compound annual growth rate (CAGR), from -$12.16M to -$70.97M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude